Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor α and carnitine palmitoyl acyl-CoA transferase 1A

被引:58
作者
Cheng, Yang [1 ]
Dharancy, Sebastien [1 ]
Malapel, Mathilde [1 ]
Desreumaux, Pierre [1 ]
机构
[1] Univ Lille, Equipe Mixte INSERM 0114, CHU, F-59037 Lille, France
基金
中国国家自然科学基金;
关键词
Hepatitis C virus; Infection; PPAR alpha; CPT1A;
D O I
10.3748/wjg.v11.i48.7591
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To elucidate the role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) and its target gene carnitine palmitoyl acyl-CoA transferase 1A (CPT1A) in the pathogenesis of hepatitis C virus (HCV) infection. METHODS: Liver samples were collected from the patients with chronic HCV infection and controls. HepG2 cells were transfected with vector pEF352neo carrying. Two independent clones (clone N3 and N4) stably expressing HCV core protein were analyzed. Total RNA was extracted from cells and liver tissues. PPAR alpha and CPT1A mRNAs were quantified by real-time polymerase chain reaction (PCR) using SYBR Green Master. Total extracted proteins were separated by polyacrylamide gel electrophoresis, and electroblotted. Membranes were incubated with the anti-PPAR alpha antibody, then with a swine anti-rabbit IgG conjugated to horseradish peroxidase for PPAR alpha. Protein bands were revealed by an enhanced chemiluminescence reaction for PPAR alpha. For immunohistochemical staining of PPAR alpha, sections were incubated with the primary goat polyclonal antibody directed against PPAR alpha at room temperature. RESULTS: Real-time PCR indicated that the PPAR alpha level and expression level of CPT1A gene in hepatitis C patients lowered significantly as compared with the controls (1.8 +/- 2.8 vs 13 +/- 3.4, P = 0.0002; 1.1 +/- 1.5 vs 7.4 +/- 1, P = 0.004). Western blot results showed that the level of PPAR alpha protein in the livers of hepatitis C patients was lower than that in controls (2.3 +/- 0.3 vs 3.6 +/- 0.2, P = 0.009). The immunohistochemical staining results in chronic hepatitis C patients indicated a decrease in PPAR alpha staining in hepatocytes compared with those in the control livers. The in vitro studies found that in the N3 and N4 colon stably expressing HCV core protein, the PPAR alpha mRNA levels were significantly lower than that in the controls. CONCLUSION: The impaired intrahepatic PPAR alpha expression is associated with the pathogenic mechanism in hepatic injury during chronic HCV infection. HCV infection reduced the expression of PPAR alpha and CPT1A at the level of not only mRNAs but also proteins. PPAR alpha plays an important role in the pathogenesis of chronic HCV infection, but the impaired function of this nuclear receptor in HCV infection needs further studies. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:7591 / 7596
页数:6
相关论文
共 36 条
[1]   Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C [J].
Asselah, T ;
Boyer, N ;
Guimont, MC ;
Cazals-Hatem, D ;
Tubach, F ;
Nahon, K ;
Daïkha, H ;
Vidaud, D ;
Martinot, M ;
Vidaud, M ;
Degott, C ;
Valla, D ;
Marcellin, P .
GUT, 2003, 52 (11) :1638-1643
[2]   Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor α-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast [J].
Bandsma, RHJ ;
van Dijk, TH ;
ter Harmsel, A ;
Kok, T ;
Reijngoud, DJ ;
Staels, B ;
Kuipers, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (10) :8930-8937
[3]   Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets [J].
Barba, G ;
Harper, F ;
Harada, T ;
Kohara, M ;
Goulinet, S ;
Matsuura, Y ;
Eder, G ;
Schaff, Z ;
Chapman, MJ ;
Miyamura, T ;
Brechot, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1200-1205
[4]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[5]  
Bièche I, 1999, CLIN CHEM, V45, P1148
[6]  
Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004
[7]   Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? [J].
Burroughs, AK ;
Groszmann, R ;
Bosch, J ;
Grace, N ;
Garcia-Tsao, G ;
Patch, D ;
Garcia-Pagan, JC ;
Dagher, L .
GUT, 2002, 50 (03) :425-427
[8]   Ragaglitazar:: a novel PPARα & PPARδ agonist with potent lipidlowering and insulin-sensitizing efficacy in animal models [J].
Chakrabarti, R ;
Vikramadithyan, RK ;
Misra, P ;
Hiriyan, J ;
Raichur, S ;
Damarla, RK ;
Gershome, C ;
Suresh, J ;
Rajagopalan, R .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (03) :527-537
[9]   The scientific challenge of hepatitis C [J].
Cohen, J .
SCIENCE, 1999, 285 (5424) :26-30
[10]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629